MARKET

MANE

MANE

VERADERMICS INC
NYSE
99.72
-6.35
-5.99%
After Hours: 101.66 +1.94 +1.95% 19:21 05/15 EDT
OPEN
103.00
PREV CLOSE
106.07
HIGH
105.84
LOW
97.80
VOLUME
476.75K
TURNOVER
--
52 WEEK HIGH
117.71
52 WEEK LOW
32.00
MARKET CAP
4.11B
P/E (TTM)
-46.9072
1D
5D
1M
3M
1Y
5Y
1D
The IPO Boom Isn't in Tech and AI -- Yet
Barron‘s · 1d ago
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
The Motley Fool · 1d ago
Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead.
Barron‘s · 1d ago
Veradermics, Incorporated (MANE) Receives a Buy from Jefferies
TipRanks · 1d ago
Veradermics To Present Two Comparative Analyses Of VDPHL01's Phase 2 Male Data Results Versus Published Data On Efficacy Of Existing Minoxidil Formulations At 2026 Music City SCALE
Benzinga · 2d ago
Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock
Simply Wall St · 2d ago
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Barchart · 2d ago
Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion
TipRanks · 2d ago
More
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Webull offers Veradermics Inc stock information, including NYSE: MANE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MANE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MANE stock methods without spending real money on the virtual paper trading platform.